RxDoctor Payments Data

Vrinda Trivedi

Cardiovascular Disease · Columbia, MONPI 1154677995

Payments from drug & device makers

$12,131in general payments, 2019–2025

Across 94 payments — averaging $129.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • Abbott$3K
  • Edwards Lifesciences$2K
  • Abiomed$375
  • Amgen$341
  • Novartis$341
  • plus $636 from 12 others

What the payments were for

  • Speaking & faculty fees$6,00049%
  • Travel & lodging$2,44520%
  • Food & beverage$3,68630%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,131 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$66,420
Medicare patients
553
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$60,633
FarxigaDapagliflozin Propanediol23$26,457
Repatha SureclickEvolocumab18$26,369
EntrestoSacubitril/Valsartan18$21,272
XareltoRivaroxaban12$18,231
Metoprolol Succinate123$1,744
Atorvastatin Calcium123$1,187
Ezetimibe35$894
Losartan Potassium79$688
Carvedilol66$574
Amlodipine Besylate79$539
Potassium Chloride31$499
Midodrine Hcl12$480
Furosemide59$471
Lisinopril48$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$60,63355 claims
AstraZenecaFarxiga$106$26,45723 claims
NovartisEntresto$341$21,27218 claims
Johnson & JohnsonXarelto$29$18,23112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →